Microtubule nucleation properties of single human γTuRCs explained by their Cryo-EM structure

The γ-tubulin ring complex (γTuRC) is the major microtubule nucleator in cells. The mechanism of its regulation is not understood. We purified human γTuRC and measured its nucleation properties in a total internal reflection fluorescence (TIRF) microscopy-based real-time nucleation assay. We find that γTuRC stably caps the minus ends of microtubules that it nucleates stochastically. Nucleation is inefficient compared with microtubule elongation. The 4 Å resolution cryoelectron microscopy (cryo-EM) structure of γTuRC, combined with crosslinking mass spectrometry analysis, reveals an asymmetric conformation with only part of the complex in a "closed" conformation matching the microtubule geometry. Actin in the core of the complex, and MZT2 at the outer perimeter of the closed part of γTuRC appear to stabilize the closed conformation. The opposite side of γTuRC is in an "open," nucleation-incompetent conformation, leading to a structural asymmetry explaining the low nucleation efficiency of purified human γTuRC. Our data suggest possible regulatory mechanisms for microtubule nucleation by γTuRC closure.This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001163 and FC0010065), the UK Medical Research Council (FC001163 and FC0010065), and the Wellcome Trust (FC001163 and FC0010065) to T.S. and A.C. The Wellcome Centre for Cell Biology is supported by core funding from the Wellcome Trust (203149). J. Rappsilber is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – EXC 2008 – 390540038 – UniSysCat and 329673113. J. Roostalu. was supported by a Sir Henry Wellcome Postdoctoral Fellowship (100145/Z/12/Z) and M.A.C. is supported by a Marie Sk1odowska-Curie Postdoctoral Fellowship (agreement no. 845939). T.S. acknowledges support from the European Research Council (Advanced Grant, project 323042). A.C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 820102). T.C., J.A., J.W.M., and T.S. acknowledge also the support of the Spanish Ministry of Economy, Industry and Competitiveness to the CRG-EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme of the Generalitat de Cataluny

Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine

<p>Abstract</p> <p>Background</p> <p>Griseofulvin, an antifungal drug, has recently been shown to inhibit proliferation of various types of cancer cells and to inhibit tumor growth in athymic mice. Due to its low toxicity, griseofulvin has drawn considerable attention for its potential use in cancer chemotherapy. This work aims to understand how griseofulvin suppresses microtubule dynamics in living cells and sought to elucidate the antimitotic and antiproliferative action of the drug.</p> <p>Methods</p> <p>The effects of griseofulvin on the dynamics of individual microtubules in live MCF-7 cells were measured by confocal microscopy. Immunofluorescence microscopy, western blotting and flow cytometry were used to analyze the effects of griseofulvin on spindle microtubule organization, cell cycle progression and apoptosis. Further, interactions of purified tubulin with griseofulvin were studied <it>in vitro </it>by spectrophotometry and spectrofluorimetry. Docking analysis was performed using autodock4 and LigandFit module of Discovery Studio 2.1.</p> <p>Results</p> <p>Griseofulvin strongly suppressed the dynamic instability of individual microtubules in live MCF-7 cells by reducing the rate and extent of the growing and shortening phases. At or near half-maximal proliferation inhibitory concentration, griseofulvin dampened the dynamicity of microtubules in MCF-7 cells without significantly disrupting the microtubule network. Griseofulvin-induced mitotic arrest was associated with several mitotic abnormalities like misaligned chromosomes, multipolar spindles, misegregated chromosomes resulting in cells containing fragmented nuclei. These fragmented nuclei were found to contain increased concentration of p53. Using both computational and experimental approaches, we provided evidence suggesting that griseofulvin binds to tubulin in two different sites; one site overlaps with the paclitaxel binding site while the second site is located at the αβ intra-dimer interface. In combination studies, griseofulvin and vinblastine were found to exert synergistic effects against MCF-7 cell proliferation.</p> <p>Conclusions</p> <p>The study provided evidence suggesting that griseofulvin shares its binding site in tubulin with paclitaxel and kinetically suppresses microtubule dynamics in a similar manner. The results revealed the antimitotic mechanism of action of griseofulvin and provided evidence suggesting that griseofulvin alone and/or in combination with vinblastine may have promising role in breast cancer chemotherapy.</p

Gradual compaction of the central spindle decreases its dynamicity in PRC1 and EB1 gene-edited cells

During mitosis, the spindle undergoes morphological and dynamic changes. It reorganizes at the onset of the anaphase when the antiparallel bundler PRC1 accumulates and recruits central spindle proteins to the midzone. Little is known about how the dynamic properties of the central spindle change during its morphological changes in human cells. Using gene editing, we generated human cells that express from their endogenous locus fluorescent PRC1 and EB1 to quantify their native spindle distribution and binding/unbinding turnover. EB1 plus end tracking revealed a general slowdown of microtubule growth, whereas PRC1, similar to its yeast orthologue Ase1, binds increasingly strongly to compacting antiparallel microtubule overlaps. KIF4A and CLASP1 bind more dynamically to the central spindle, but also show slowing down turnover. These results show that the central spindle gradually becomes more stable during mitosis, in agreement with a recent "bundling, sliding, and compaction" model of antiparallel midzone bundle formation in the central spindle during late mitosis.This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001163), the UK Medical Research Council (FC001163), and the Wellcome Trust (FC001163). T Surrey acknowledges support from the European Research Council (Advanced Grant, project 323042). J Asthana, D Normanno, WM Lim, and T Surrey acknowledge also the support of the Spanish Ministry of Economy, Industry and Competitiveness to the CRG-EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme of the Generalitat de Cataluny

A Synthetic Dolastatin 10 Analogue Suppresses Microtubule Dynamics, Inhibits Cell Proliferation, and Induces Apoptotic Cell Death

We have synthesized eight analogues (<b>D1</b>–<b>D8</b>) of dolastatin 10 containing several unique amino acid subunits. Of these agents, <b>D5</b> was found to be most effective in inhibiting both HeLa cell proliferation and microtubule assembly in vitro. At low nanomolar concentrations, <b>D5</b> inhibited the proliferation of several types of cancer cells in culture. <b>D5</b> bound to tubulin with a dissociation constant of 29.4 ± 6 μM. <b>D5</b> depolymerized microtubules in cultured cells and produced mulitpolar spindles. At its half-maximal inhibitory concentration (15 nM), <b>D5</b> strongly suppressed the dynamics of individual microtubules in live MCF-7 cells. <b>D5</b> increased the accumulation of checkpoint proteins BubR1 and Mad2 at the kinetochoric region and caused G2/M block in these cells. The blocked cells underwent apoptosis with the activation of Jun N-terminal kinase. The results suggested that <b>D5</b> exerts its antiproliferative action by dampening microtubule dynamics

Design of nickel chelates of tetradentate N-heterocyclic carbenes with subdued cytotoxicity

A series of nickel complexes, 1b-3b, exhibiting subdued cytotoxicity have been designed with the intent of their use as agents for developing resistance to nickel toxicity. Indeed, the nickel complexes, 1b-3b, display less cytotoxic activity towards two commonly occurring human cancer cell lines namely, HeLa cells (16-64%) and MCF-7 cells (70-90%) in culture as compared to the maximum inhibition by NiCl2·6H2O under analogous conditions at three different concentrations (1&#956;M, 5&#956;M and 20&#956;M). Similarly, the suppression of cytotoxicity through chelation of the metal ion can also be seen in normal cells as was evident from a significant reduction in cytotoxicity (9-41%) for a non-tumorigenic CHO cell line in case of a representative complex 3b. The reduction in carcinogenic activity in the complexes relative to nickel(II) ion from NiCl2·6H2O is brought about by successful chelation of the metal center by a class of specially designed new tetradentate N/O-functionalized N-heterocyclic carbene ligands. The two strongly &#963;-donating carbene moieties coupled with two negatively charged amido moieties present in the N-heterocyclic carbene ligands facilitate complete chelation of the metal center and thereby significantly reduce the cytotoxic effects of the metal